乳房再造风险评估计算器的外部验证
该研究对接受假体乳房再造的患者进行BRA Score模型外部验证,纳入855例患者(1333侧乳房)。结果显示SSI和血清肿模型校准良好,包膜取出模型校准欠佳,三个模型均有良好区分度。
要点
- BRA Score对SSI和血清肿预测校准良好,包膜取出预测校准欠佳
- SSI、血清肿、包膜取出的C统计量分别为0.73、0.69、0.78
- BRA Score模型可用于预测假体乳房再造30天结局
核心结论
- BRA Score组织扩张器/假体再造模型总体校准、区分度和准确性良好,部分模型存在弱点需改进。
主要发现
- 共审查1152例患者(1743侧乳房),其中855例患者(1333侧乳房)数据完整并纳入分析。
- SSI和血清肿模型的Hosmer-Lemeshow检验P值分别为0.33和0.16,预测与观察结果一致。
- 包膜取出模型的Hosmer-Lemeshow检验P值为0.04,预测率与观察率存在偏差。
- SSI、血清肿和包膜取出模型的C统计量分别为0.73、0.69和0.78,区分度良好。
临床怎么用
- BRA Score可用于假体乳房再造患者术前30天并发症风险的个体化评估。
局限性
- 部分模型(如包膜取出)校准欠佳,需未来改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Breast reconstruction Risk Assessment (BRA) Score estimates patient-specific risk for postsurgical complications using an individual's unique combination of preoperative variables. In this report, we externally validate the BRA Score models for surgical site infection, seroma, and explantation in a large sample of intra-institutional patients who underwent prosthetic breast reconstruction. METHODS: We reviewed all initiated tissue expander/implant reconstructions by the senior authors from January 2004 to December 2015. BRA Score risk estimates were computed for each patient and compared against observed rates of complications. Hosmer-Lemeshow goodness-of-fit test, concordance statistic, and Brier score were used to assess the calibration, discrimination, and accuracy of the models, respectively. RESULTS: Of the 1152 patients (1743 breasts) reviewed, 855 patients (1333 breasts) had complete data for BRA-score calculations and were included for analysis. Hosmer-Lemeshow tests for calibration demonstrated a good agreement between observed and predicted outcomes for surgical site infection (SSI) and seroma models (P-values of 0.33 and 0.16, respectively). In contrast, predicted rates of explantation deviated from observed rates (Hosmer-Lemeshow P-value of 0.04). C statistics demonstrated good discrimination for SSI, seroma, and explantation (0.73, 0.69, and 0.78, respectively). CONCLUSIONS: In this external validation study, the BRA Score tissue expander/implant reconstruction models performed with generally good calibration, discrimination, and accuracy. Some weaknesses in certain models were identified as targets for future improvement. Taken together, these analyses validate the clinical utility of the BRA score risk models in predicting 30-day outcomes.
引用
- Khavanin N, Qiu CS, Mlodinow AS, et al. External validation of the breast reconstruction risk assessment calculator. J Plast Reconstr Aesthet Surg. 2017. PMID: 28539245. doi:10.1016/j.bjps.2017.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。